Review of Transfusion Medicine:
Clinical Use of Blood



James Kelley, PhD, MD

Department of Pathology
Brigham and Women's Hospital
Harvard Medical School

jmkelley@partners.org



Alabama

Alabama Department of Tourism

Boston, Massachusetts, USA

Photos: Flickr.com

Partners HealthCare

- 12 Hospitals and 35 clinics
  - Massachusetts General Hospital
  - Brigham and Women's Hospital
- Primary affiliate of Harvard Medical School
- Serves over 2 million patients annually
- 54,000 full time employees
- Generates US$ 4+ billion annual revenue
- Academically produced 11 Nobel Laureates
- Administers 150,000+ transfusions annually

WHO Blood Transfusion Integrated Strategies

1.) Nationally coordinated transfusion service
    Quality control systems

2.) Voluntary non-remunerated “low-risk” donors

3.) Solid laboratory practices
    Testing for transfusion transmitted infections and compatibility
    Proper processing, storage, and transportation of blood

4.) Appropriate clinical use of blood
    Reducing unnecessary transfusions



World Health Organization. (2001)

Clinical Use of Blood

Can I prescribe another therapy, such as hematinics, surgical optimization, or IV fluids, to support this patient successfully?

If **yes**, please eliminate unnecessary blood transfusion.
If **no**, please transfuse blood appropriately.

What happens to a unit of donated blood?

Approximately 450-500 mL of whole blood collected

Leukoreduced when possible

Irradiated before use

Undergoes differential centrifugation

Infectious disease testing

190-220 mL of RBC

225-250 mL of plasma

35-50 mL of platelets

130 cc of preservative

citrate, adenine, dextrose, mannitol



Blood Components



Red Blood Cells
Platelets
Plasma

Cryoprecipitate
Granulocytes
Plasma Fractions*

Photos: ScienceLibrary.com

RBC transfusion guidelines

Red Blood Cells

Clinical setting	Transfusion may be indicated for Hct below:
Oncology/BMT Pregnant Preoperative anemia	26%
Acute coronary syndrome Major thoracic surgery w/ postop anemia	30%
Normovolemic, non-bleeding patient, none of above apply	21%

Platelet transfusion guidelines

Platelets

Clinical setting	Transfusion may be indicated for PLT below:
Prophylaxis (nonbleeding patient):	
- Stable patient, no procedure planned - Central line removal	10,000/μL
- Hem/Onc pt. with recent minor bleeding	20,000/μL
- Central line placement or paracentesis	30,000/μL
- Major extracranial surgery - Lumbar puncture, thoracentesis or biopsy	50,000/μL
- CNS or ophthalmologic surgery	100,000/μL
Bleeding patient:	
- Intraop or postop	50,000/μL
- After cardiopulmonary bypass	100,000/μL

Platelet Refractoriness

Normal platelet response

Increase in platelet count by 30-50 k/μL per unit transfused

Platelet refractoriness

Corrected count increase less than 5-10 k/μL per unit transfused

$$CCI = \frac{\text{post-transfusion platelet increment X body surface area } (m^2)}{\text{platelets transfused } (10^{11})}$$

Increase in platelet count less than 11 k/μL per unit transfused

Counts drawn between 15-60 minutes after transfusion

Platelet "bump" < 11k/μL indicates immune mediated mechanism



Platelet Refractoriness



Non-immune causes of poor platelet response (> 11k/μL increase)

Most common cause of poor platelet response

Sepsis / Fever increases platelet consumption
Cancer increases platelet consumption / alters production
Drugs increases platelet consumption / alters production
Disseminated Intravascular Coagulation (DIC)
Graft versus host disease (GVHD)
Splenomegaly sequesters platelets
Hematopoietic cell therapy – inconsistent data
Older platelets have reduced lifespan and function
ABO mismatch may trigger mild hemolytic reaction and destruction
Unrecognized surgical bleeding
Veno-occlusive disease

Physicians can write orders for "freshest ABO compatible" platelets.

Platelet response is dependent on correcting underlying defect.

Platelet Refractoriness

Drugs that can induce thrombocytopenia

Acetaminophen
Acetazolamide
Aminoglutethimide
Amphotericin B
Amrinone
Amiodarone
Atorvastatin
Augmentin
Asparaginase
Bactrim (TMP/SMX)
Barbiturates
Captopril
Carbamazepine
Cefotetan
Cephalothin
Chloramphenicol
Chloroquine
Chlorothiazide
Chlorpromazine
Chlorpropamide
Cimetidine
Codeine
Cyclophosphamide
Dalteparin
Danazol
Desipramine
Diazepam
Diazoxide
Diclofenac
Diethylstilbestrol
Digoxin
Enoxaparin
Eptifibatide
Erythromycin
Estrogen
Ethambutol
Famotidine
Fluconazole
Fluorouracil
Furosemide
Gemcitabine
Gold Salts
Gentamicin
Glyburide
Haloperidol
Heparin
Hydrochlorothiazide
Imipenem
Indinavir
Indomethacin
Interferon Alfa
Iopanoic Acid
Isoniazid
Levamisole
Linezolid
Lansoprazole
Lithium
Meloxicam
Meperidine
Meprobamate
Mesalamine
Methicillin
Methyldopa
Methimazole
Minoxidil
Methotrexate
Nitroglycerin
Omeprazole
Pantoprazole
Penicillamine
Penicillins
Pentoxifylline
Phenothiazine's
Phenylbutazone
Phenytoin
Piperacillin
Prednisone
Procarbazine
Propylthiouracil
Quinine
Quinidine
Rabeprazole
Ranitidine
Reserpine
Rifampin
Sinemet (Levodopa)
Streptomycin
Sulfasalazine
Sulfonamides
Sulindac
Tamoxifen
Tetracycline
Tirofiban (Aggrastat)
Ticlopidine
Tolbutamide
Valproic Acid
Vancomycin



PARTNERS HEALTHCARE

Platelet Refractoriness



"Immune" causes of poor platelet response (< 11k/μL increase)

- Anti-HLA antibodies
- Anti-platelet antibodies (drug induced)
- Frequent transfusions decrease subsequent platelet response

Order Panel Reactive Antibody (PRAFlow) Test to detect anti-HLA

- Reactivity > 30% indicates clinically significant anti-HLA antibodies
- Assay uses beads with class I and II HLA

Anti-HLA antibodies require HLA matched donor platelets

- Platelets express HLA class I; Reactions typical to HLA-A and HLA-B
- Order HLA class I typing on recipients (coordinate with BMT teams)

Optimize transfusion recommendations

- Order HPA antibody screening
- Crossmatch platelets (solid-phase red cell adherence test)

Plasma transfusion guidelines

Plasma	
Clinical setting	**Transfusion may be indicated for INR above:**
Active bleeding or Prior to major surgery or invasive procedure*	1.5

*FFP prophylaxis is not indicated for central line placement/removal.

FFP dosing:
10-15 ml/kg (1 unit of FFP has a volume of ~250 ml)
Urgent warfarin reversal:
- **Vitamin K** (5 mg IV infused over 10 minutes) is recommended in addition to FFP unless reversal is intended to be transient. - **Life-threatening hemorrhage on warfarin**: in addition to FFP and vitamin K, prothrombin complex concentrate (Profilnine) is recommended. **Profilnine dosing:** INR <4.0: Profilnine 25 U/kg slow IV push INR ≥4.0: Profilnine 50 U/kg slow IV push

Cryoprecipitate transfusion guidelines

Cryoprecipitate	
Clinical setting	**Transfusion may be indicated for fibrinogen below:**
Active bleeding or hemostatic challenge	100 mg/dL

“Cryo” contains fibrinogen and some von Willebrand Factor and Factor VIII.

It is not a concentrated form of plasma.

It can also be used for TPA reversal and snake envenomation.

Plasma derivatives

Albumin
- Diuretic resistant edema in hypoproteinemic patients
- Therapuetic apheresis (plasma exchange)
- Replacement fluid – no evidence better than crystalloids

Factor VIII
- Hemophilia A and von Willebrand Disease

Factor IX (Prothrombin complex concentrate)
- Hemophilia B
- Warfarin reversal

Anti-D antibodies (RhoGham)

Immunoglobulins (IV or IM)
- IVIg
- Specific to antigen (i.e. rabies, HBV)

Whole Blood Transfusions

Whole blood transfusions are NOT recommended when blood components are available.

Indications / testing are similar to RBC transfusion.

It should be leukoreduced and irradiated.

Increased risk of transfusion reactions

Febrile non-hemolytic reaction
Allergic reaction
Volume overload
Transfusion related graft vs host disease

Used in limited military settings



J Trauma. 2006;61:181–184

Blood Typing (ABO Compatibility)



ABO red blood cell antigens

- Front typing – patients' RBC with known antibodies
- Reverse typing – patients' serum with known RBC

Rh (D) red blood cell antigen

There are many other clinically relevant red blood cell antigens not tested for in a type and screen.

Antibody screen uses two known RBC and patients' serum to look for agglutination.

- IgM – at room temperature (immediate spin)
- IgG – after adding anti-human IgG antibodies

Blood Typing (ABO Compatibility)



Serology Panel if Antibody Screen Positive



Cell #	Rh-hr	Donor Number	Rh-hr D	Rh-hr C	Rh-hr E	Rh-hr c	Rh-hr e	Rh-hr f	Rh-hr Cw	Rh-hr V	KELL K	KELL k	KELL Kpa	KELL Kpb	KELL Jsa	KELL Jsb	DUFFY Fya	DUFFY Fyb	KIDD Jka	KIDD Jkb	Sis Linked	LEWIS Lea	LEWIS Leb	MNS S	MNS s	MNS U	MNS Hil	P	LUTHERAN Lua	LUTHERAN Lub	Special Antigen Typing	Test Results
1	R1wR1	303382	+	+	0	0	+	0	+	0	0	-	0	+	0	+	-	0	+	+	-	0	+	-	-	-	-	+s	0	+		1 0 2
2	R1R1	305883	+	+	0	0	+	0	0	0	+	+	0	+	0	+	+	+	+	0	+	+	0	+	+	0	+	+	0	+		2 0 2
3	R2R2	304520	+	0	+	+	0	0	0	0	0	+	0	+	0	+	+	+	0	+	+	0	+	0	+	+	0	+	0	+		3 0 0 ✓
4	Ror	305371	+	0	0	+	+	+	0	0	0	+	0	+	0	✓	0	0	+	+	0	0	0	0	+	+	0	+	0	+		4 0 0 ✓
5	rr	115379	0	+	0	+	+	+	0	0	0	+	0	-	0	+	0	0	+	0	+	0	0	+	0	-	-	+s	0	+		5 0 1
6	rr	117673	0	0	+	+	+	+	0	0	0	+	+	+	0	+	0	+	+	+	+	+	0	+	0	-	+	+	0	+	●	6 2 0 ✓
7	rr	114312	0	0	0	+	+	+	0	0	+	+	0	+	0	+	0	+	0	+	+	+	0	0	+	+	+	+	0	+	●	7 0 0 ✓
8	rr	109989	0	0	0	+	+	+	0	0	0	+	0	+	0	+	+	+	+	0	+	0	+	+	0	+	0	+	0	+	●	8 0 0 ✓
9	rr	114436	0	0	0	+	+	+	0	0	0	+	0	+	0	+	+	0	+	+	+	0	+	+	+	0	+	+	0	+		9 0 0 ✓
10	rr	306221	0	0	0	+	+	+	0	0	+	+	0	+	0	+	+	+	0	+	+	0	+	0	+	+	0	+	0	+		10 0 0 ✓
11	R1R1	306255	+	+	0	0	+	0	0	0	0	+	0	+	0	+	0	-	0	-	-	0	+	-	-	-	0	0	0	+		11 0 2 ✓
	Patient Cells	AUTO	1		1						1																					0 0 ✓
Mode of Reactivity			37°C/Antiglobulin								Antiglobulin											Variable		Cold				Var.				

* If antigen status may have been determined presumptively based on Rh-hr phenotype

ORTHO* ANTIBODY INDEX CHART

Blood Group System	Antibody	Common Reaction Mode RT	37C	AHG	Transfusion Reaction	H D N	Reactivity With Enzyme Treated RBC	% Blood Compatibility Whites	Blacks
Rh-hr	D	■	■	■	Probable	Common	Increased	15	
	C	■	■	■	Probable	May	Increased	30	
	E	■	■	■	Probable	May	Increased	70	
	c	■	■	■	Probable	Common	Increased	20	
	e	■	■	■	Probable	May	Increased	3	
	f	■	■	■	Probable	May	Increased	33	
	C^w	■	■	■	Probable	May	Increased	98	
	V	■	■	■	Probable	No reports	Increased	100	82
Kell	K			■	Probable	May	Same	90	97
	k			■	Probable	May	Same	0.2	<0.1
	Kp^a			■	Probable	May	Same	98	>99
	Kp^b			■	Probable	May	Same	<0.1	<0.1
	Js^a			■	Probable	May	Same	>99	80
	Js^b			■	Probable	May	Same	0	<0.1
Duffy	Fy^a			■	Probable	May	Decreased	33	89
	Fy^b			■	Probable	May	Decreased	20	77
Kidd	Jk^a			■	Probable	May	Increased	25	9
	Jk^b			■	Probable	May	Increased	25	57
Lewis	Le^a	■	■	■	May	Not usually	Increased	78	82
	Le^b	■	■	■	Unlikely	Not usually	Increased	28	40
MNS	S			■	Probable	May	Variable	45	69
	s			■	Probable	May	Variable	11	3
	M	■	■		Unlikely	Not usually	Decreased	22	30
	N	■	■		Unlikely	Not usually	Decreased	28	26
	U			■	Probable	May	Same	0	<1
P	P_1	■	■	■	Unlikely	Not usually	Increased	21	5
	P	■	■	■	Probable	No reports	Increased	<0.1	
	$P+P_1+P^k$	■	■	■	Probable	May	Increased	<0.1	
Lutheran	Lu^a	■	■		Unlikely	Not usually	Variable	92	
	Lu^b			■	Probable	May	Variable	<1.0	
HTLA	Yk^a			■	Unlikely	Not usually	Decreased	8	2
	Kn^a			■	Unlikely	Not usually	Same	1	
	Cs^a			■	Unlikely	Not usually	Same	2	
	Ch^a			■	Unlikely	Not usually	Decreased	2	
	Rg^a			■	Unlikely	Not usually	Decreased	3	
	JMH			■	Unlikely	Not usually	Decreased	<1	
	McC^a			■	Unlikely	Not usually	Same	2	7



What causes antibody formation (alloimmunization)?

Chronic transfusions

- Sickle cell anemia
- Thalassemia
- Hematological malignancies

Previous pregnancies

Transfusion-related risks

Risks per unit	
Human immunodeficiency virus (HIV)	1:2,000,000
Hepatitis C virus	1:2,000,000
Hepatitis B virus	1:200,000
West Nile Virus	Approaching 0
Bacteria (PLT transfusion)	1:75,000
Febrile or allergic reaction	1:100
Circulatory overload	1:400
Transfusion Related Acute Lung Injury (TRALI)	1:5,000

Transfusion Transmitted Infections (TTIs)



Strategies to reduce transfusion transmitted infections

- Voluntary non-remunerated donors
- Laboratory testing
- Donor deferral and confidential unit exclusion
- Callback procedures

Hepatitis A – no screening test, questionnaire only
***Hepatitis B** – core antibody, surface antigen, NAT
***Hepatitis C** - ELISA, RIBA, NAT (32 day window)
***HIV** – ELISA (p24, HIV 1/2), Western blot, NAT (12 day window)
***HTLV** - ELISA (HTLV 1/2), Western blot, NAT
***Syphilis** – RPR, organism does not tolerate 4°C well
CMV – leukoreduction

Transfusion Transmitted Infections (TTIs)

Malaria – blood smear, travel questionnaire
Babesiosis – PCR
Chagas Disease – travel questionnaire, ELISA
CJD (prion disease) – travel questionnaire
Chikungunya – travel questionnaire

Sepsis (bacterial contamination)

RBC – Gram negative rods, older units (25 days), can be fatal
Platelets – Gram positive cocci

Effect of interventions on TTI



Busch, et al. (2001)

Transfusion Reactions

Allergic reactions
- Urticarial reactions
- Anaphylactic reactions

Febrile non-hemolytic reactions
Acute hemolytic reactions
Delayed hemolytic reactions
Transfusion associated circulatory overload (TACO)
Transfusion related acute lung injury (TRALI)
Transfusion associated graft vs host disease
Bacterial contamination of blood (sepsis)



Urticarial reactions

Symptoms:

Hives (not anaphylaxis)



Mechanism:

Histamine-mediated response to soluble antigen in donor plasma

Treatment:

Hold transfusion

Treat with diphenhydramine

Can restart transfusion

Prevention:

Pre-medicate

Washed blood products

plasma based products

Test for IgA deficiency

Anaphylactic reactions

Symptoms:

- Anaphylaxis
- Flushing
- Hives
- Respiratory compromise

Mechanism:

- Same as urticarial
- Atopic individuals

Treatment:

- Hold transfusion
- Treat with diphenhydramine
- Treat with steroids
- Treat with epinephrine
- Do not restart transfusion

Prevention:

- Pre-medicate
- Washed blood products
- Test for IgA deficiency
- Transfuse only emergently

Febrile non-hemolytic transfusion reaction

Symptoms:

- Increase in temp by 1°C
- Chills / rigors
- Absence of other causes

Management:

- Stop transfusion
- Treat with anti-pyretic
- Test for hemolysis
- Test for other causes

Mechanism:

- Cytokines in blood product

Prevention:

- Leukoreduction

Hemolytic transfusion reaction

Symptoms:

- Fever
- Chills
- SOB
- Back / flank / epigastric pain
- Anxiety
- Oliguria / hemoglobinuria
- Hypotension / shock

Management:

- Blood bank:
  - Clerical check
  - Repeat type and screen
  - Check for hemolysis
  - DAT
- Clinicians:
  - Stop transfusion
  - Maintain IV access
  - Monitor BP / urine output

Mechanism:

- Antibody mediated hemolysis
- Clerical error

Prevention:

- Patient identification
- Cross-match



Transfusion associated circulatory overload (TACO)

Symptoms:

- SOB
- Cough
- Decrease in O_2 saturation
- Pulmonary edema
- Hypertension

Mechanism:

- High oncotic pressure
  Common in infants / elderly
- Common in CHF patients

Management:

- Hold transfusion
- Forced diuresis (furosemide)
- Supportive care

Prevention:

- Slower transfusions



Transfusion associated lung injury (TRALI)

Symptoms:

- SOB
- Cough
- Decrease in O_2 saturation
- Bilateral pulmonary edema
- Hyper- or hypotension
- Tachycardia
- Onset within 6 hours
- Absence of TACO

Mechanism:

- Donor anti-HLA antibodies

Management:

- Supportive
- Mortality 5-10%
- Chest x-ray

Prevention:

- Male plasma
- Deferral of implicated donors



Transfusion associated lung injury (TRALI)





Septic transfusion reaction

Symptoms:

- Fever
- Chills
- Septic shock

Mechanism:

- Bacterial contamination
- Common with platelets

Management:

- Culture blood bag
- Culture patient
- Treat sepsis

Prevention:

- Donor selection
- Collection technique

WHO Blood Transfusion Integrated Strategies

1.) Nationally coordinated transfusion service
    Quality control systems

2.) Voluntary non-remunerated “low-risk” donors

3.) Solid laboratory practices
    Testing for transfusion transmitted infections and compatibility
    Proper processing, storage, and transportation of blood

4.) Appropriate clinical use of blood
    Reducing unnecessary transfusions



World Health Organization. (2001)

Autologous / directed donations



“I want my own blood during surgery next week.**”**

Directed Donation

Regular donors repeat frequently.

Most directed are first time donors.

Autologous Donation

Takes ~1 month to replenish blood

Preservation reduces efficacy by 30%

Drops patient’s RBC count

Voluntary non-remunerated donors

WHO: Unnecessary Blood Transfusions



Treating based on a number rather than presentation

- "I want a Hct > 30% before I go to the operating room."
- "My oncology patients must have Hb > 8 at all times."
- Follow guidelines established nationally.

Used as primary treatment for anemia

- Hematinics, nutrient supplementation as appropriate
- Transfuse RBC only when oxygen delivery does not meet patient's needs

Used as first-line volume expander

- Crystalloids, colloids, IV replacement fluids

To compensate for less optimal surgical management

World Health Organization. (2001)

Clinical Use of Blood

Can I prescribe another therapy, such as hematinics, surgical optimization, or IV fluids, to support this patient successfully?

jmkelley@partners.org